Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Divests Azmacort For $200 Mil.; Kos To Back Relaunch With 500 Reps

Executive Summary

Kos Pharmaceuticals will relaunch Azmacort with a 490-representative sales force following its $200 mil. purchase of the inhaled corticosteroid from Aventis

You may also be interested in...



Kos Will Re-Launch Teveten And Cardizem LA In June Following Biovail Deal

Kos will re-launch Biovail's three cardiovascular products in June following the addition of 150 Biovail reps to its sales team

Kos Will Re-Launch Teveten And Cardizem LA In June Following Biovail Deal

Kos will re-launch Biovail's three cardiovascular products in June following the addition of 150 Biovail reps to its sales team

Aventis Defense Against Sanofi: Strong Pipeline Or Irrational “Exubera-nce”?

Aventis is using the prospects of Genasense as its first line of defense against Sanofi's hostile takeover bid

Related Content

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel